Table 1.
Characteristics and dyslipidemia risk among early-stage breast cancer patients.
| Menopausal status | |||||
|---|---|---|---|---|---|
| Group | All (n = 1,883) | Postmenopause (n = 625) | Premenopause (n = 1,258) | ||
| Age, median (IQR) | 46.00 [41.00–53.00] | 57.00 [52.00–62.00] | 43.00 [39.00–47.00] | ||
| 47.31 (9.63) | 57.42 (7.18) | 42.28 (6.10) | |||
| BMI, median (IQR) | 22.58 [20.70–24.69] | 23.44 [21.23–25.63] | 22.22 [20.45–24.14] | ||
| 22.88 (3.02) | 23.63 (3.16) | 22.51 (2.88) | |||
| Stage, n (%) | 0 | 36 (1.9) | 11 (1.8%) | 25 (2.0%) | |
| I | 433 (23.0) | 141 (22.6%) | 292 (23.2%) | ||
| II | 887 (47.1) | 297 (47.5%) | 590 (46.9%) | ||
| III | 431 (22.9) | 159 (25.4%) | 272 (21.6%) | ||
| Unknown | 96 (5.1) | 17 (2.7%) | 79 (6.3%) | ||
| pT status, n (%) | 0 | 45 (2.4) | 17 (2.7%) | 28 (2.2%) | |
| 1 | 668 (35.5) | 229 (36.6%) | 439 (34.9%) | ||
| 2 | 891 (47.3) | 307 (49.1%) | 584 (46.4%) | ||
| 3 | 79 (4.2) | 18 (2.9%) | 61 (4.8%) | ||
| 4 | 109 (5.8) | 43 (6.9%) | 66 (5.2%) | ||
| Unknown | 91 (4.8) | 11 (1.8%) | 80 (6.4%) | ||
| pM status, n (%) | 0 | 1,883 (100.0) | 625 (100.0%) | 1,258 (100.0%) | |
| pN status, n (%) | 0 | 927 (49.2) | 293 (46.9%) | 634 (50.4%) | |
| 1 | 593 (31.5) | 196 (31.4%) | 397 (31.6%) | ||
| 2 | 207 (11.0) | 78 (12.5%) | 129 (10.3%) | ||
| 3 | 144 (7.6) | 51 (8.2%) | 93 (7.4%) | ||
| Unknown | 12 (0.6) | 7 (1.1%) | 5 (0.4%) | ||
| Subtype, n (%) | Luminal A | 297 (15.8) | 83 (13.3%) | 214 (17.0%) | |
| Luminal B (Her2 +) | 299 (15.9) | 91 (14.6%) | 208 (16.5%) | ||
| Luminal B \(Her2 −) | 752 (39.9) | 237 (37.9%) | 515 (40.9%) | ||
| TNBC | 22 (1.2) | 12 (1.9%) | 10 (0.8%) | ||
| Her2 positive | 25 (1.3) | 10 (1.6%) | 15 (1.2%) | ||
| Unknown | 488 (25.9) | 192 (30.7%) | 296 (23.5%) | ||
| ER, n (%) | Negative | 139 (7.4) | 67 (10.7%) | 72 (5.7%) | |
| Positive | 1,714 (91.0) | 543 (86.9%) | 1,171 (93.1%) | ||
| Unknown | 30 (1.6) | 15 (2.4%) | 15 (1.2%) | ||
| PR, n (%) | Negative | 253 (13.4) | 139 (22.2%) | 114 (9.1%) | |
| Positive | 1,599 (84.9) | 471 (75.4%) | 1,128 (89.7%) | ||
| Unknown | 31 (1.6) | 15 (2.4%) | 16 (1.3%) | ||
| HER2, n (%) | Negative | 1,198 (63.6) | 384 (61.4%) | 814 (64.7%) | |
| Positive | 357 (19.0) | 118 (18.9%) | 239 (19.0%) | ||
| Unknown | 328 (17.4) | 123 (19.7%) | 205 (16.3%) | ||
| KI67, n (%) | <14% | 418 (22.2) | 128 (20.5%) | 290 (23.1%) | |
| ≥14% | 1,369 (72.7) | 460 (73.6%) | 909 (72.3%) | ||
| Unknown | 96 (5.1) | 37 (5.9%) | 59 (4.7%) | ||
| Comorbidity a , n (%) | No | 1,669 (88.6) | 475 (76.0%) | 1,194 (95.0%) | |
| Yes | 214 (11.4) | 150 (24.0%) | 64 (5.1%) | ||
| TC (mmol/L), median (IQR) | 4.82 [4.29–5.33] | 4.98 [4.44–5.45] | 4.74 [4.22–5.25] | ||
| Mean (SD) | 4.79 (0.72) | 4.92 (0.71) | 4.72 (0.72) | ||
| TG (mmol/L), median (IQR) | 1.33 [1.01–1.66] | 1.42 [1.09–1.72] | 1.28 [0.97–1.64] | ||
| Mean (SD) | 1.35 (0.43) | 1.42 (0.42) | 1.32 (0.43) | ||
| HDL-C (mmol/L), median (IQR) | 1.43 [1.25–1.67] | 1.41 [1.23–1.65] | 1.45 [1.27–1.68] | ||
| Mean (SD) | 1.49 (0.32) | 1.47 (0.31) | 1.50 (0.32) | ||
| LDL-C (mmol/L), median (IQR) | 2.80 [2.37–3.23] | 2.93 [2.50–3.37] | 2.75 [2.31–3.16] | ||
| Mean (SD) | 2.79 (0.61) | 2.91 (0.61) | 2.73 (0.60) | ||
| Follow-up (months), median (range) | 31.68 [0.03–60.00] | 31.79 [0.13–60.00] | 31.58 [0.03–60.00] | ||
| No. of events within 5 years | 467 | 193 | 274 | ||
| Durations from baseline to dyslipidemia (months), median (range) | 7.77 [1.03–59.23] | 7.45 [1.06–59.23] | 8.35 [1.03–57.00] | ||
| Incidence within 1 year [95% CI] | 17.2% [18.9%–15.4%] | 22.3% [25.6%–18.8%] | 14.6% [16.7%–12.6%] | ||
| Incidence within 5 years [95% CI] | 34.7% [37.7%–31.7%] | 41.7% [46.7%–36.3%] | 31.2% [34.7%–27.5%] | ||
aComorbidity for hypertension, diabetes, and chronic kidney disease; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2; TNBC, triple-negative breast cancer; TC, total cholesterol; TG, triglyceride; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol.